All In Biotech

Drug Trial Radar · NCT02512042

Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes

A Multicentre, Double Blind, Active Controlled, Parallel Group, Two Arm, Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension (Manufactured by Indoco Remedies Ltd. for Watson Pharma Pvt Ltd.), to Brinzolamide (Azopt®) 1% Ophthalmic Suspension of Alcon Laboratories, Inc., In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes

Last checked: Nov 20, 2026Latest source record: Mar 2, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 973 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

973

Actual

Start

Apr 2015

Primary completion

Apr 2016

Study completion May 2016

Sponsor

Lead sponsor
Actavis Inc.Industry
Sponsor type
Industry
First posted
Jul 30, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Other
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double blind, two-arm, parallel group, active controlled bioequivalence study, at multiple clinical trial sites designed to demonstrate bioequivalence of Brinzolamide 1% ophthalmic suspension (manufactured by Indoco Remedies Ltd. for Watson Pharma Pvt Ltd.), to Brinzolamide (Azopt®) 1% ophthalmic suspension of Alcon Laboratories, Inc. in the treatment of chronic open angle glaucoma or ocular hypertension in both eyes.

Conditions

  • Glaucoma

Interventions

  • Test-Brinzolamide 1% Ophthalmic suspensionDrug

  • Reference-Brinzolamide 1% Ophthalmic suspensionDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Difference in Intraocular Pressure (IOP) of Both Eyes Between the Two Treatment Groups at Four Time PointsTime frame: Day 14 and 42 at 8AM and 10AM

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • David Wirta, MD

    Newport Beach, California

  • Shettle Eye Research, Inc.

    Largo, Florida

  • AMB Research Center, Inc.

    Miami, Florida

  • Eye Care Centers Management, Inc.

    Morrow, Georgia

  • Coastal Research Associates, LLC

    Roswell, Georgia

  • Heart of America Eye Care PA

    Shawnee Mission, Kansas

  • Ophthalmology Associates

    St Louis, Missouri

  • Las Vegas Physicians Research Group

    Henderson, Nevada

  • Keystone Research Ltd.

    Austin, Texas

  • Keystone Research Ltd.

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.